GT BIOPHARMA, INC. Proceeds from Sale of Equity Method Investments
GT BIOPHARMA, INC. (GTBP) reported Proceeds from Sale of Equity Method Investments of $3.53 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2023-05-15
- GT BIOPHARMA, INC. proceeds from sale of equity method investments for the quarter ending 2022-03-31 was $3.53M.
| Period end | Proceeds from Sale of Equity Method Investments 3 month |
|---|---|
| 2022-03-31 | $3.53M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |